Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Siva Suryadevara"'
Autor:
Francesco Franchi, MD, Fabiana Rollini, MD, Victor Kairouz, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Maryuri Briceno, MD, Mustafa Wali, MD, Ahmed Nawaz, MD, Gabriel Silva, MD, Zubair Shaikh, MD, Naji Maaliki, MD, Latonya Been, AAS, Jason Piraino, DPM, Andres M. Pineda, MD, Siva Suryadevara, MD, Daniel Soffer, MD, Martin M. Zenni, MD, Lisa K. Jennings, PhD, Theodore A. Bass, MD, Dominick J. Angiolillo, MD, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 4, Iss 7, Pp 763-775 (2019)
Summary: Vorapaxar reduces thrombotic cardiovascular events at the expense of increased bleeding. However, the differential pharmacodynamic (PD) effects of vorapaxar according to diabetes mellitus (DM) status are unknown. Moreover, although withdrawa
Externí odkaz:
https://doaj.org/article/b7ea15f9ac70419180a5ce0ec8e4c853
Autor:
Francesco Franchi, Fabiana Rollini, Gabriel Faz, Jose Ramon Rivas, Andrea Rivas, Malhar Agarwal, Maryuri Briceno, Mustafa Wali, Ahmed Nawaz, Gabriel Silva, Zubair Shaikh, Naji Maaliki, Kerolos Fahmi, Latonya Been, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Usman Baber, Roxana Mehran, Lisa K. Jennings, Theodore A. Bass, Dominick J. Angiolillo
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 8 (2020)
Background Vorapaxar as an adjunct to dual antiplatelet therapy (DAPT) reduces thrombotic events in patients with prior myocardial infarction at the expense of increased bleeding. Withdrawal of aspirin has emerged as a bleeding reduction strategy. Th
Externí odkaz:
https://doaj.org/article/febf58ad375f48bcb33144fe435a90c7
Autor:
Francesco Franchi, Luis Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Birgit Reiter, Bernd Jilma, Dominick J. Angiolillo
Publikováno v:
JACC: Cardiovascular Interventions. 16:36-46
Autor:
Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda Maldonado, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick Angiolillo
Publikováno v:
Thrombosis and Haemostasis.
Background:To date, there is no data on switching to dual pathway inhibition (DPI) patients who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen. Objectives: To assess the feasibility of switching from DAPT to DPI and t
Autor:
Francesco, Franchi, Luis, Ortega-Paz, Fabiana, Rollini, Latonya, Been, Andrea, Rivas, Naji, Maaliki, Xuan, Zhou, Andres M, Pineda, Siva, Suryadevara, Daniel, Soffer, Martin, Zenni, Dominick J, Angiolillo
Publikováno v:
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
The impact of intense low-density lipoprotein cholesterol (LDL-C) reduction using a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on profiles of platelet reactivity has yet to be explored.Our aim was to investigate the effects of th
Autor:
Salvatore Giordano, Francesco Franchi, Luis Ortega-paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Birgit Reiter, Bernd Jilma, Dominick J Angiolillo
Publikováno v:
European Heart Journal Supplements. 24
Objectives To rule out a drug-drug interaction (DDI) among cangrelor-treated patients who have been pre-treated with ticagrelor. Background There are no studies specifically designed to rule out a DDI when cangrelor is used among patients who have be
Autor:
Salvatore Giordano, Luis Ortega-paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres M. Pineda, Siva Suryadevara, Daniel Soffer, Martin M. Zenni, Lisa K Jennings, Dominick J. Angiolillo
Publikováno v:
European Heart Journal Supplements. 24
Aims To assess the feasibility of switching from dual antiplatelet therapy (DAPT) to dual pathway inhibition (DPI) and to compare the pharmacodynamic (PD) profiles of these treatment regimens. Methods and results This was a prospective, randomized, P
Autor:
Francesco, Franchi, Luis, Ortega-Paz, Fabiana, Rollini, Mattia, Galli, Latonya, Been, Ghussan, Ghanem, Awss, Shalhoub, Tiffany, Ossi, Andrea, Rivas, Xuan, Zhou, Andres M, Pineda, Siva, Suryadevara, Daniel, Soffer, Martin M, Zenni, Dominick J, Angiolillo
Publikováno v:
JACC. Cardiovascular interventions.
To rule out a drug-drug interaction (DDI) among cangrelor-treated patients who have been pre-treated with ticagrelor.There are no studies specifically designed to rule out a DDI when cangrelor is used among patients who have been pre-treated with tic
Autor:
Martin M. Zenni, Francesco Franchi, Mattia Galli, Andres M. Pineda, Xuan Zhou, Latonya F. Been, Siva Suryadevara, Ghussan Ghanem, Dominick J. Angiolillo, Theodore A. Bass, Andrea Rivas, Daniel Soffer, Awss Shalhoub, Fabiana Rollini
Publikováno v:
JACC: Cardiovascular Interventions. 14:2410-2412
Autor:
Mattia Galli, Francesco Franchi, Fabiana Rollini, Latonya Been, Patrick Abou Jaoude, Andrea Rivas, Xuan Zhou, Sida Jia, Naji Maaliki, Chang Hoon Lee, Andres M Pineda, Siva Suryadevara, Daniel Soffer, Martin M Zenni, Tobias Geisler, Lisa K Jennings, Theodore A Bass, Dominick J Angiolillo
Publikováno v:
European heart journal. Cardiovascular pharmacotherapy. 8(7)
Aims Dual pathway inhibition (DPI) by adding a vascular dose of rivaroxaban to a single antiplatelet agent has emerged as a promising antithrombotic strategy. However, in most studies the antiplatelet agent of choice used in adjunct to a vascular dos